Franklin Resources Inc. Increases Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Franklin Resources Inc. increased its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,285 shares of the financial services provider’s stock after purchasing an additional 580 shares during the quarter. Franklin Resources Inc.’s holdings in iShares Biotechnology ETF were worth $2,664,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Blue Fin Capital Inc. increased its holdings in shares of iShares Biotechnology ETF by 0.7% in the second quarter. Blue Fin Capital Inc. now owns 10,516 shares of the financial services provider’s stock worth $1,443,000 after buying an additional 74 shares during the period. Security National Bank of SO Dak grew its position in iShares Biotechnology ETF by 0.7% during the 2nd quarter. Security National Bank of SO Dak now owns 10,461 shares of the financial services provider’s stock worth $1,436,000 after acquiring an additional 75 shares during the last quarter. SPC Financial Inc. increased its stake in iShares Biotechnology ETF by 2.4% in the 3rd quarter. SPC Financial Inc. now owns 3,265 shares of the financial services provider’s stock worth $475,000 after purchasing an additional 75 shares during the period. Werba Rubin Papier Wealth Management lifted its position in iShares Biotechnology ETF by 2.7% in the third quarter. Werba Rubin Papier Wealth Management now owns 2,918 shares of the financial services provider’s stock valued at $425,000 after purchasing an additional 76 shares during the last quarter. Finally, Main Street Financial Solutions LLC boosted its stake in shares of iShares Biotechnology ETF by 1.0% during the second quarter. Main Street Financial Solutions LLC now owns 8,002 shares of the financial services provider’s stock valued at $1,098,000 after purchasing an additional 82 shares during the period. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Stock Performance

Shares of iShares Biotechnology ETF stock opened at $133.95 on Thursday. The company’s 50 day moving average price is $140.19 and its 200-day moving average price is $142.23. iShares Biotechnology ETF has a 52-week low of $123.60 and a 52-week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.